.avif)
Applications of the genO‑panhCD3/hFcγR mouse model
Useful applications for researchers working in different biomedical fields, such as immuno-oncology, inflammation and autoimmunity:
- Assess the efficacy of CD3-targeting antibodies and TCEs and understand the contribution of the Fc region:
- Perform tumor growth inhibition assays in the context of monotherapies or combotherapies
- Test TCEs for inhibition of autoimmune diseases
- Ex vivo assessment of antibody-dependent cellular cytotoxicity (ADCC) induced by different monoclonal antibodies
- Rank Fc-engineered antibodies with enhanced or reduced binding to FcγR
- Gain insight into the mechanism of action (MOA) of diverse constructs and their potential therapeutic benefit
- Evaluate the safety and toxicity of compounds
- Analyze the biodistribution of hFcγR-targeting compounds and activated effector cells
- Suitable for toxicological assessments, including those relating to reproductive toxicity, as an alternative to non-human primate (NHP) models.
Features
This model combines the features of two extensively validated models: genO-panhCD3 and genO-hFcγR.
- genO‑panhCD3/hFcγR mice have a human-like FcγR expression pattern and physiological expression of humanized CD3edg (ε, δ and γ)
- Expression of the following humanized receptors: FcγRI (CD64), FcγRIIA (CD32A), FcγRIIB (CD32B), FcγRIIIA (CD16A), FcγRIIIB (CD16B)
- Functional Fcγ receptors enable the assessment of Fc-mediated effector functions
- Functional CD3/TCR interaction
- Functional T/B-cell cooperation
- No expression of murine FcγR nor murine CD3
- Fully immunocompetent model
Guides: Compare FcγR and CD3 mouse models and select the most relevant platform for evaluating therapeutic antibodies and Fc-mediated mechanisms. Read the FcγR guide or the CD3 guide.
Clients
No items found.
